The Minnesota Legislature's historically productive session has prompted a flurry of legal challenges, many arguing that Democratic lawmakers overstepped their constitutional authority.
A national trade group representing generic drug manufacturers sued Minnesota on Wednesday over a new law meant to minimize prescription drug price increases. Two new election laws have also been challenged — including one that restored voting rights for felons, as well as another law relating to the state's Postsecondary Enrollment Options (PSEO) program.
"I think they were all easy to anticipate," GOP state Rep. Harry Niska, an attorney, said of the lawsuits, adding that he raised concerns about the constitutionality of the legislative actions during the session. "It's unfortunate that those concerns weren't taken into consideration before we went forward with the laws."
Democratic lawmakers and the state attorney general have expressed confidence that the new laws will prevail in court.
"We know from past experience that the pharmaceutical industry will challenge any attempt to rein in drug prices," said Sen. Kelly Morrison, DFL-Deephaven, who sponsored the prescription drug proposal. "They have every right to challenge this law, but I am confident that the law is both constitutional and necessary."
The prescription drug law prohibits "excessive" price increases for generic or off-patent drugs. It defines an excessive price increase as being 15% or more in a single year or 40% or more over three years.
The Association for Accessible Medicines filed the suit seeking to block the law, which it called an "unconstitutional overreach" that "grants Minnesota unprecedented powers to regulate the national pharmaceutical market." The group said the law violates the federal commerce clause and asked a judge to prevent the state from enforcing it.
"Minnesota is rejecting generic competition in favor of more government regulation — of generic drugs, the only segment of health care costs that is actually declining," David Gaugh, the association's interim president and CEO, said in a statement. "If this new law is enforced, it will harm patients and our communities by reducing choice and limiting access to essential medicines that people need."